Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 7/20 | 0.34 |
| ▸ | IDH1 | O75874 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | TYK2 | P29597 | 1/20 | 0.30 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.30 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.30 |
| ▸ | PDE1C | Q14123 | 3/20 | 0.30 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20831759 | 0.92 | ATR (0.33) | ATRIDH1JAK2JAK1TYK2 | |
| SCHEMBL20818474 | 0.90 | ATR (0.33) | ATRJAK2JAK1TYK2CYP4F2 | |
| SCHEMBL20817777 | 0.89 | IDH1 (0.35) | ATRIDH1 | |
| SCHEMBL20818143 | 0.85 | PDE9A (0.31) | ATRIDH1 | |
| SCHEMBL20817999 | 0.82 | ATR (0.33) | ATRIDH1JAK2JAK1TYK2 | |
| SCHEMBL20831549 | 0.82 | IDH1 (0.34) | ATRIDH1JAK2JAK1TYK2 | |
| SCHEMBL20818320 | 0.79 | TRPC5 (0.40) | — | |
| SCHEMBL20831944 | 0.79 | TRPC5 (0.40) | — | |
| SCHEMBL20818318 | 0.79 | TRPC5 (0.40) | — | |
| SCHEMBL24433293 | 0.79 | IDH1 (0.37) | ATRIDH1CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2023-06-29 | — | — | US | disclosed |
| US-20220152031-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. | 2022-05-19 | — | — | US | disclosed |
| WO-2020191056-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
| WO-2019055966-A2 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | PDXK, ATP6V1B1, REN | ATR 3541/4885IDH1 1443/4885JAK2 2912/4885 |
| US-20220152031-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GLS, ATP6V1B1, PDXK | ATR 4398/4885IDH1 778/4885JAK2 2576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.